Clinical trial

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-06-05

PhasePHASE2

Study timeline

Study start (actual)2024-06-05Date precision: day

Registry last updated2026-05-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Metastatic Breast Cancerunresolved

Interventions

Trastuzumab-Deruxtecan (T-DXd)DRUG

Sponsors & collaborators

MedSIRlead sponsor

Daiichi Sankyocollaborator

Mapped research locations

MadridMadrid, Spain2 BarcelonaBarcelona, Spain2 ViennaAustria1 SalzburgAustria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06048718 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.